AB
OVID icon

Amalgamated Bank’s Ovid Therapeutics OVID Stock Holding History

Amalgamated Bank’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,011
Closed -$1K – 3105
2025
Q1 		$1K Hold
2,011
– – ﹤0.01% 2924
2024
Q4 		$2K Hold
2,011
– – ﹤0.01% 2915
2024
Q3 		$2K Hold
2,011
– – ﹤0.01% 2941
2024
Q2 		$2K Hold
2,011
– – ﹤0.01% 2961
2024
Q1 		$6K Sell
2,011
-3,191
-61% -$10.7K ﹤0.01% 2661
2023
Q4 		$17K Sell
5,202
-598
-10% -$2.04K ﹤0.01% 2722
2023
Q3 		$22K Hold
5,800
– – ﹤0.01% 2618
2023
Q2 		$19K Buy
+5,800
New +$19.7K ﹤0.01% 2771

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Amalgamated Bank's OVID Position: Q2 2025 in Review

Amalgamated Bank sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 2,011 shares — an estimated $1K sold.

Amalgamated Bank first reported a position in OVID in Q2 2023 and held it in 8 quarters. The position peaked at $22K in Q3 2023. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Amalgamated Bank reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 2,011 Ovid Therapeutics shares in Q2 2025, an estimated $1K.
  • Amalgamated Bank first reported a position in Ovid Therapeutics in Q2 2023 and held it in 8 quarters.
  • Amalgamated Bank's Ovid Therapeutics position peaked at $22K in Q3 2023.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.